XpresSpa Group to Open Additional XpresCheck Testing Facilities at Houston George Bush Intercontinental Airport and Newark Li...
January 25 2021 - 8:30AM
XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”),
a health and wellness company, today announced that it will be
opening two new XpresCheck testing facilities in United Airlines
airport terminals. In the coming weeks, XpresCheck will
open its first facility in Houston’s George Bush
Intercontinental Airport and a second facility in Newark
Liberty International Airport.
Doug Satzman, XpresSpa CEO, stated, “We are
pleased to leverage our existing relationship with United Airlines
to bring new XpresCheck testing facilities to Newark and Houston.
Partnering with United helps bring the convenience of on-site
COVID-19 testing to passengers, whether they are traveling to a
destination that requires a negative COVID-19 test for entry or
they are seeking to test out of their home state-mandated
quarantine. Our ability to provide trusted test results within an
airport setting is providing people with an added layer of security
and comfort as their demand for travel increases.”
XpresCheck will begin building a pop-up facility
in George Bush Intercontinental Airport within United Terminal E,
post-security, this week. This facility will host four separate
testing rooms with an anticipated capacity to administer over 300
tests per day. COVID-19 testing options will include the Rapid
Molecular COVID-19 Test and the Polymerase Chain Reaction (PCR)
Test. The Company expects this facility to open in early March.
XpresCheck has started building a pop-up
facility in Newark Liberty International Airport within United’s
Terminal C baggage claim area, pre-security. This facility will
host four separate testing rooms with an anticipated capacity to
administer over 300 tests per day. COVID-19 testing options will
include the Rapid Molecular COVID-19 Test and the Polymerase Chain
Reaction (PCR) Test. The Company expects this facility to open in
mid-February.
“United is committed to offering our customers
convenient testing options to help them manage their travel and
assist with meeting their destination’s entry requirements,” said
Toby Enqvist, chief customer officer at United. “Working with
XpresCheck allows us to further expand customer COVID-19 testing
offerings as we lead the way in providing greater accessibility to
tests to more customers at more of our hub airports.”
About XpresSpa Group, Inc.
XpresSpa Group, Inc. (Nasdaq: XSPA) is a
leading global health and wellness holding company. XpresSpa
Group’s core asset, XpresSpa, is a leading airport retailer of
spa services and related health and wellness products, with 45
locations in 23 airports globally. Through its XpresTest,
Inc. subsidiary, the Company provides COVID-19 screening and
testing under the XpresCheck™ brand at seven locations in six
airports: Denver International Airport, JFK International
Airport, Logan International Airport (2), Newark
Liberty International Airport, Phoenix Sky Harbor
International Airport, and Salt Lake City International Airport. To
learn more about XpresSpa Group,
visit: www.XpresSpaGroup.com. To learn more
about XpresSpa, visit www.XpresSpa.com. To learn more
about XpresCheck,
visit www.XpresCheck.com.Twitter: @xprescheck and
Instagram: @realxprescheck
About United Airlines
United's shared purpose is "Connecting People.
Uniting the World." For more information, visit united.com,
follow @United on Twitter and Instagram or connect on Facebook. The
common stock of United's parent, United Airlines Holdings, Inc., is
traded on the Nasdaq under the symbol "UAL".
Forward-Looking Statements
This press release may contain "forward-looking"
statements within the meaning of Section 27A of the Securities Act
of 1933, and Section 21E of the Securities Exchange Act of 1934.
These include statements preceded by, followed by or that otherwise
include the words "believes," "expects," "anticipates,"
"estimates," "projects," "intends," "should," "seeks," "future,"
"continue," or the negative of such terms, or other comparable
terminology. In particular, these statements include, without
limitation, statements about our expectations relating to our new
XpresCheck™ concept, being able to expand testing to other
communicable diseases as well as administer vaccinations for the
seasonal flu, our positioning to be part of the national rollout of
various COVID-19 vaccinations as they become available, the degree
to which our public testing model assists passengers meet testing
requirements in select states and countries, our ability to
identify and gain access to the latest and best COVID-19 testing
methodologies and equipment, and our ability further expand our
initial sites and our overall ability to manage the regulatory
challenges associated with this business line. Forward-looking
statements relating to expectations about future results or events
are based upon information available to XpresSpa Group as
of today's date and are not guarantees of the future performance of
the company, and actual results may vary materially from the
results and expectations discussed. Additional information
concerning these and other risks is contained in XpresSpa Group’s
most recently filed Annual Report on Form 10-K, Quarterly Report on
Form 10-Q, recent Current Reports on Form 8-K and
other Securities and Exchange Commission filings. All
subsequent written and oral forward-looking statements
concerning XpresSpa Group, or other matters and attributable
to XpresSpa Group or any person acting on its behalf are
expressly qualified in their entirety by the cautionary statements
above. XpresSpa Group does not undertake any obligation
to publicly update any of these forward-looking statements to
reflect events or circumstances that may arise after the date
hereof.
Media - XpresSpaJulie Ferguson
Julie@jfprmedia.com(312) 385-0098
Investor Relations -
XpresSpaICRRaphael Grossir@xpresspa.com (203)
682-8253
XpresSpa (NASDAQ:XSPA)
Historical Stock Chart
From Mar 2024 to Apr 2024
XpresSpa (NASDAQ:XSPA)
Historical Stock Chart
From Apr 2023 to Apr 2024